INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 45h ago
HOUSE PTR5h ago
SEC 13F5h ago
ROBINHOOD CHAIN5h ago
Public company

SUPNIndivior Pharmaceuticals, Inc.

CIK 0001625297

EDGAR filingsOpen in network
Disclosed transactions34
Buys / sells5 / 2
Max Insider Score41
Connections9with evidence

SUPN · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
36
AD
Anderson Woodrow DChief Accounting Officer
INDVIndivior Pharmaceuticals, Inc.
Open-market purchase
BUY$54K
1,500 sh
Aug 27, 2026Aug 27, 2026
traded Aug 27, 2026
+0dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2834 · Pharmaceutical Preparations · Nov 4, 2026
  • ← Disclosed trade inevidence
    Gilbert Ray Cisneros, Jr.Purchase disclosed 2026-04-07 · Apr 7, 2026
  • ← Insider ofevidence
    Heidbreder ChristianChief Scientific Officer · Feb 12, 2026
  • ← Insider ofevidence
    Anderson Woodrow DChief Accounting Officer · Feb 12, 2026
20
HC
Heidbreder ChristianChief Scientific Officer
INDVIndivior Pharmaceuticals, Inc.
Open-market sale · 10b5-1 plan
SELL
$707K
18.6K sh
Jun 11, 2026
Jun 12, 2026
traded Jun 11, 2026
+1d
SEC FORM 4

Evidence

23
PR
Preblick RyanChief Financial Officer
INDVIndivior Pharmaceuticals, Inc.
Open-market sale · 10b5-1 plan
SELL$1.36M
36.0K sh
Jun 8, 2026Jun 10, 2026
traded Jun 8, 2026
+2dSEC FORM 4

Evidence

17
RB
Ryan BarbaraDirector
INDVIndivior Pharmaceuticals, Inc.
Grant or award
A—
6,518 sh
May 13, 2026May 14, 2026
traded May 13, 2026
+1dSEC FORM 4

Evidence

17
HK
Humphreys KeithDirector
INDVIndivior Pharmaceuticals, Inc.
Grant or award
A—
6,518 sh
May 13, 2026May 14, 2026
traded May 13, 2026
+1dSEC FORM 4

Evidence

28
Gilbert Ray Cisneros, Jr.DSelf
SUPNIndivior Pharmaceuticals, Inc.
Purchase
BUY$1,001 – $15KMar 3, 2026Apr 7, 2026
traded Mar 3, 2026
+35dHOUSE PTR

Evidence

9
PR
Preblick RyanChief Financial Officer
INDVIndivior Pharmaceuticals, Inc.
Option exercise
M—
6,302 sh
Mar 14, 2026Mar 17, 2026
traded Mar 14, 2026
+3dSEC FORM 4

Evidence

9
PR
Preblick RyanChief Financial Officer
INDVIndivior Pharmaceuticals, Inc.
Option exercise
M—
6,302 sh
Mar 14, 2026Mar 17, 2026
traded Mar 14, 2026
+3dSEC FORM 4

Evidence

12
PR
Preblick RyanChief Financial Officer
INDVIndivior Pharmaceuticals, Inc.
Tax withholding
F$88K
2,843 sh
Mar 14, 2026Mar 17, 2026
traded Mar 14, 2026
+3dSEC FORM 4

Evidence

9
AD
Anderson Woodrow DChief Accounting Officer
INDVIndivior Pharmaceuticals, Inc.
Option exercise
M—
24.0K sh
Mar 3, 2026Mar 5, 2026
traded Mar 3, 2026
+2dSEC FORM 4

Evidence

27
AD
Anderson Woodrow DChief Accounting Officer
INDVIndivior Pharmaceuticals, Inc.
Tax withholding
F$265K
8,283 sh
Mar 3, 2026Mar 5, 2026
traded Mar 3, 2026
+2dSEC FORM 4

Evidence

9
HC
Heidbreder ChristianChief Scientific Officer
INDVIndivior Pharmaceuticals, Inc.
Option exercise
M—
132.6K sh
Mar 3, 2026Mar 5, 2026
traded Mar 3, 2026
+2dSEC FORM 4

Evidence

9
AD
Anderson Woodrow DChief Accounting Officer
INDVIndivior Pharmaceuticals, Inc.
Option exercise
M—
5,946 sh
Mar 3, 2026Mar 5, 2026
traded Mar 3, 2026
+2dSEC FORM 4

Evidence

16
AD
Anderson Woodrow DChief Accounting Officer
INDVIndivior Pharmaceuticals, Inc.
Tax withholding
F$86K
2,682 sh
Mar 3, 2026Mar 5, 2026
traded Mar 3, 2026
+2dSEC FORM 4

Evidence

30
PR
Preblick RyanChief Financial Officer
INDVIndivior Pharmaceuticals, Inc.
Tax withholding
F$2.80M
87.6K sh
Mar 3, 2026Mar 5, 2026
traded Mar 3, 2026
+2dSEC FORM 4

Evidence

17
PR
Preblick RyanChief Financial Officer
INDVIndivior Pharmaceuticals, Inc.
Option exercise
M—
86.9K sh
Mar 3, 2026Mar 5, 2026
traded Mar 3, 2026
+2dSEC FORM 4

Evidence

9
PR
Preblick RyanChief Financial Officer
INDVIndivior Pharmaceuticals, Inc.
Option exercise
M—
113.5K sh
Mar 3, 2026Mar 5, 2026
traded Mar 3, 2026
+2dSEC FORM 4

Evidence

21
HC
Heidbreder ChristianChief Scientific Officer
INDVIndivior Pharmaceuticals, Inc.
Option exercise
M—
101.5K sh
Mar 3, 2026Mar 5, 2026
traded Mar 3, 2026
+2dSEC FORM 4

Evidence

26
HC
Heidbreder ChristianChief Scientific Officer
INDVIndivior Pharmaceuticals, Inc.
Tax withholding
F$1.46M
45.8K sh
Mar 3, 2026Mar 5, 2026
traded Mar 3, 2026
+2dSEC FORM 4

Evidence

21
AD
Anderson Woodrow DChief Accounting Officer
INDVIndivior Pharmaceuticals, Inc.
Option exercise
M—
18.4K sh
Mar 3, 2026Mar 5, 2026
traded Mar 3, 2026
+2dSEC FORM 4

Evidence

17
AD
Anderson Woodrow DChief Accounting Officer
INDVIndivior Pharmaceuticals, Inc.
Option exercise
M—
5,946 sh
Mar 3, 2026Mar 5, 2026
traded Mar 3, 2026
+2dSEC FORM 4

Evidence

15
AD
Anderson Woodrow DChief Accounting Officer
INDVIndivior Pharmaceuticals, Inc.
Grant or award
A—
24.0K sh
Feb 9, 2026Feb 12, 2026
traded Feb 9, 2026
+3dSEC FORM 4

Evidence

21
AD
Anderson Woodrow DChief Accounting Officer
INDVIndivior Pharmaceuticals, Inc.
Grant or award
A—
6,903 sh
Feb 10, 2026Feb 12, 2026
traded Feb 10, 2026
+2dSEC FORM 4

Evidence

13
PR
Preblick RyanChief Financial Officer
INDVIndivior Pharmaceuticals, Inc.
Grant or award
A—
37.4K sh
Feb 10, 2026Feb 12, 2026
traded Feb 10, 2026
+2dSEC FORM 4

Evidence

15
PR
Preblick RyanChief Financial Officer
INDVIndivior Pharmaceuticals, Inc.
Grant or award
A—
113.5K sh
Feb 9, 2026Feb 12, 2026
traded Feb 9, 2026
+3dSEC FORM 4

Evidence

17
HC
Heidbreder ChristianChief Scientific Officer
INDVIndivior Pharmaceuticals, Inc.
Grant or award
A—
33.6K sh
Feb 10, 2026Feb 12, 2026
traded Feb 10, 2026
+2dSEC FORM 4

Evidence

15
HC
Heidbreder ChristianChief Scientific Officer
INDVIndivior Pharmaceuticals, Inc.
Grant or award
A—
132.6K sh
Feb 9, 2026Feb 12, 2026
traded Feb 9, 2026
+3dSEC FORM 4

Evidence

13
WE
Wheadon David E.Director
INDVIndivior Pharmaceuticals, Inc.
Grant or award
A—
5,955 sh
Jan 26, 2026Jan 28, 2026
traded Jan 26, 2026
+2dSEC FORM 4

Evidence

17
RB
Ryan BarbaraDirector
INDVIndivior Pharmaceuticals, Inc.
Grant or award
A—
3,722 sh
Jan 26, 2026Jan 28, 2026
traded Jan 26, 2026
+2dSEC FORM 4

Evidence

21
TJ
Thompson JulietDirector
INDVIndivior Pharmaceuticals, Inc.
Grant or award
A—
3,722 sh
Jan 26, 2026Jan 28, 2026
traded Jan 26, 2026
+2dSEC FORM 4

Evidence

17
HK
Humphreys KeithDirector
INDVIndivior Pharmaceuticals, Inc.
Grant or award
A—
3,722 sh
Jan 26, 2026Jan 28, 2026
traded Jan 26, 2026
+2dSEC FORM 4

Evidence

33
HK
Humphreys KeithDirector
INDVIndivior Pharmaceuticals, Inc.
Open-market purchase · 10b5-1 plan
BUY$27K
775 sh
Jan 5, 2026Jan 7, 2026
traded Jan 5, 2026
+2dSEC FORM 4

Evidence

41
RB
Ryan BarbaraDirector
INDVIndivior Pharmaceuticals, Inc.
Open-market purchase · 10b5-1 plan
BUY$27K
775 sh
Jan 5, 2026Jan 7, 2026
traded Jan 5, 2026
+2dSEC FORM 4

Evidence

36
WE
Wheadon David E.Director
INDVIndivior Pharmaceuticals, Inc.
Open-market purchase · 10b5-1 plan
BUY$63K
1,771 sh
Jan 5, 2026Jan 7, 2026
traded Jan 5, 2026
+2dSEC FORM 4

Evidence

  • ← Insider ofevidence
    Preblick RyanChief Financial Officer · Feb 12, 2026
  • ← Insider ofevidence
    Thompson JulietDirector · Jan 28, 2026
  • ← Insider ofevidence
    Wheadon David E.Director · Jan 7, 2026
  • ← Insider ofevidence
    Ryan BarbaraDirector · Jan 7, 2026
  • ← Insider ofevidence
    Humphreys KeithDirector · Jan 7, 2026